Mariner
GMAB icon

Mariner’s Genmab GMAB Stock Holding History

Mariner’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.51M Buy
56,309
+509
+0.9% +$15.3K ﹤0.01% 1687
2025
Q4 		$1.72M Buy
55,800
+8,224
+17% +$256K ﹤0.01% 1586
2025
Q3 		$1.46M Buy
47,576
+10,423
+28% +$254K ﹤0.01% 1636
2025
Q2 		$768K Sell
37,153
-3,906
-10% -$80.2K ﹤0.01% 1996
2025
Q1 		$804K Buy
41,059
+4,359
+12% +$91.4K ﹤0.01% 1840
2024
Q4 		$766K Sell
36,700
-1,079
-3% -$23.7K ﹤0.01% 1841
2024
Q3 		$921K Sell
37,779
-1,644
-4% -$44K ﹤0.01% 1678
2024
Q2 		$991K Buy
39,423
+1,731
+5% +$49.1K ﹤0.01% 1505
2024
Q1 		$1.13M Buy
37,692
+811
+2% +$23.8K ﹤0.01% 1425
2023
Q4 		$1.17M Sell
36,881
-12,137
-25% -$381K ﹤0.01% 1327
2023
Q3 		$1.73M Buy
49,018
+31,720
+183% +$1.21M ﹤0.01% 1034
2023
Q2 		$656K Sell
17,298
-6,093
-26% -$243K ﹤0.01% 1557
2023
Q1 		$883K Sell
23,391
-3,454
-13% -$133K ﹤0.01% 1340
2022
Q4 		$1.14M Buy
26,845
+9,156
+52% +$377K ﹤0.01% 1172
2022
Q3 		$568K Buy
+17,689
New +$621K ﹤0.01% 1345

Other funds holding GMAB

OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Mariner's GMAB Position: Q1 2026 in Review

Mariner increased its Genmab (GMAB) stake by 0.91% in Q1 2026, buying an estimated $15.3K and bringing the position to 56,309 shares worth $1.51M. The position accounts for ﹤0.01% of the portfolio, ranked #1687.

Mariner first reported a position in GMAB in Q3 2022 and has held it in 15 quarters since. The position peaked at $1.73M in Q3 2023. 272 funds tracked by Wall St. Rank hold GMAB as of Q1 2026.

  • Mariner held 56,309 shares of Genmab worth $1.51M as of Q1 2026.
  • Mariner bought 509 Genmab shares in Q1 2026, an estimated $15.3K.
  • Genmab made up ﹤0.01% of Mariner's portfolio in Q1 2026, its #1687 holding.
  • Mariner first reported a position in Genmab in Q3 2022 and has held it in 15 quarters since.
  • Mariner's Genmab position peaked at $1.73M in Q3 2023.
  • 272 funds tracked by Wall St. Rank held Genmab as of Q1 2026.

Based on Mariner's 13F filing for Q1 2026, filed 13 May 2026.